To 2020, the participation of biological medicines in the entire pharmaceutical market will increase to nearly 30%. The veterinary market will ... More

Founder and President of Bioceltix is of two natures – the one of an experienced scientist and the one of an entrepreneur, subjecting medical ... More

Between May 25 and 27, the largest Poland-based meeting in of individual investors with entities related to the capital market in Eastern Europe ... More

How are biopharmaceuticals produced in bioreactors? What makes them different from traditional drugs made via chemical synthesis? What is the ... More

At the beginning of May, specialists from Bioceltix – jointly with engineers from the Czech-based Block company – conducted functional tests ... More

A stem-cell therapy carried out in the allogeneic setting, standing for one donor-many recipients, enables the manufacture of a batch of the ... More

One of last year’s beneficiaries of Sub-measure 1.1.1 of the Intelligent Development Operational Program 2014-2020 is Bioceltix, a Wroclaw ... More

What dormant power lies in stem cells? How to unleash this power?   Thus far, MSCs have remained unavailable for veterinary therapies. By ... More

Our production and quality control facilities are being upgraded to cGMP standards. More equipment designed for quality control of stem ... More

We have concluded a contract with the Czech company BLOCK for a cGMP-compliant modular cell production system for clinical applications, to be ... More